Halofuginone is primarily used in veterinary medicine as an antiprotozoal agent, particularly effective against coccidiosis in poultry and livestock. It works by inhibiting the growth of the parasite, thereby preventing the disease and improving animal health and productivity. Additionally, it has shown potential in treating fibrotic conditions in humans, such as scleroderma and liver fibrosis, by inhibiting the synthesis of type I collagen. Research is ongoing to explore its application in cancer therapy, as it may inhibit angiogenesis and tumor growth. Its ability to modulate immune responses is also being investigated for potential use in autoimmune diseases.